ValuEngine upgraded shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a sell rating to a hold rating in a report issued on Thursday.
A number of other research firms also recently weighed in on BLPH. Zacks Investment Research upgraded shares of Bellerophon Therapeutics from a hold rating to a buy rating and set a $2.25 price target on the stock in a research note on Thursday, March 22nd. HC Wainwright reiterated a buy rating on shares of Bellerophon Therapeutics in a research report on Tuesday, March 20th.
BLPH opened at $2.10 on Thursday. Bellerophon Therapeutics has a 1-year low of $1.00 and a 1-year high of $2.74. The company has a market capitalization of $119.33, a PE ratio of -2.33 and a beta of -0.39.
A number of large investors have recently bought and sold shares of BLPH. Virtu Financial LLC acquired a new stake in Bellerophon Therapeutics during the 4th quarter worth approximately $146,000. Bank of New York Mellon Corp acquired a new stake in Bellerophon Therapeutics during the 4th quarter worth approximately $458,000. EAM Investors LLC acquired a new stake in Bellerophon Therapeutics during the 4th quarter worth approximately $614,000. Vanguard Group Inc. boosted its position in Bellerophon Therapeutics by 52.6% during the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after buying an additional 211,111 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Bellerophon Therapeutics by 25.3% during the 4th quarter. Renaissance Technologies LLC now owns 927,200 shares of the biotechnology company’s stock worth $2,392,000 after buying an additional 187,200 shares during the period. Institutional investors and hedge funds own 57.57% of the company’s stock.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.